Original Research
Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study

https://doi.org/10.1016/j.jcmg.2018.08.024Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

This study assessed changes in optical coherence tomography (OCT)-defined plaque composition in patients with ST-elevation myocardial infarction (STEMI) receiving high-intensity statin treatment.

Background

OCT is a high-resolution modality capable of measuring plaque characteristics including fibrous cap thickness (FCT) and macrophage infiltration. There is limited in vivo evidence regarding the effects of statins on OCT-defined coronary atheroma composition and no evidence in the context of STEMI.

Methods

In the IBIS-4 (Integrated Biomarker Imaging Study-4), 103 patients underwent intravascular ultrasonography and OCT of 2 noninfarct-related coronary arteries in the acute phase of STEMI. Patients were treated with high-dose rosuvastatin for 13 months. Serial OCT imaging was available in 153 arteries from 83 patients. We measured FCT by using a semi-automated method. Co-primary endpoints consisted of the change in minimum FCT (measured in fibroatheromas) and change in macrophage line arc.

Results

At 13 months, median low-density lipoprotein cholesterol had decreased from 128 mg/dl to 73.6 mg/dl. Minimum FCT, measured in 31 lesions from 27 patients, increased from 64.9 ± 19.9 μm to 87.9 ± 38.1 μm (p = 0.008). Macrophage line arc decreased from 9.6° ± 12.8° to 6.4° ± 9.6° (p < 0.0001). The secondary endpoint, mean lipid arc, decreased from 55.9° ± 37° to 43.5° ± 33.5°. In lesion-level analyses (n = 191), 9 of 13 thin-cap fibroatheromata (TCFAs) at baseline (69.2%) regressed to non-TCFA morphology, whereas 2 of 178 non-TCFA lesions (1.1%) progressed to TCFAs.

Conclusions

In this observational study, we found significant increase in minimum FCT, reduction in macrophage accumulation, and frequent regression of TCFAs to other plaque phenotypes in nonculprit lesions of patients with STEMI treated with high-intensity statin therapy.

Key Words

atherosclerosis
myocardial infarction
optical coherence tomography
plaque composition
statin

Abbreviations and Acronyms

CAD
coronary artery disease
FCT
fibrous cap thickness
IRA
infarct-related artery
IVUS
intravascular ultrasonography
MI
myocardial infarction
OCT
optical coherence tomography
ROI
region of interest
STEMI
ST-segment elevation myocardial infarction
TCFA
thin-cap fibroatheroma
ThCFA
thick-cap fibroatheroma

Cited by (0)

The IBIS-4 trial was funded by Swiss National Science Foundation grants 33CM30-124112 and 310030-118353, St. Jude Medical/Abbott, Zurich, Switzerland, and Biosensors SA, Morges, Switzerland. Dr. Raber has received research grants from St. Jude Medical/Abbott, Sanofi, and Regeneron; and has received speaker fees from Amgen and AstraZeneca. Dr. Radu has received lecture honoraria from St. Jude Medical/Abbott Vascular; and has received research grants from Abbott Vascular, Terumo, Boston Scientific, Biotronik, and Medtronic. Dr. Lüscher has received research grants and speaker fees from Amgen, AstraZeneca, Bayer Healthcare, Biosensors, Biotronik, Boston Scientific, Eli Lilly, Medtronic, Merck and Co., Roche, and Servier; Dr. Matter has received research grants and speaker fees from and consults for Eli Lilly, AstraZeneca, Roche, Amgen, and Merck and Co. Dr. Windecker has received research contracts from Bracco, Boston Scientific, and St. Jude. All other authors have reported that they have no relationships with industry relevant to the contents of this paper to disclose.